Home › Kanser sa Baga › Oklahoma › Oklahoma City
Pag-aaral pangklinika para sa Kanser sa Baga sa Oklahoma City, OK
19 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Oklahoma City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Oklahoma Health Sciences Center, Oklahoma City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Nagre-recruitPhase 3
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Mercy Hospital Oklahoma City, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Nagre-recruitPhase 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Nagre-recruitPhase 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- University of Oklahoma, Oklahoma City
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Site 101, Oklahoma City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Xencor Investigative Site, Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Nagre-recruitObservasyonal na pag-aaral
- Hightower Clinical, Oklahoma City
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Chicago, IL41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
Iba pang pag-aaral sa Oklahoma City
- Non-Small Cell Lung Cancer28 pag-aaral
- Kanser sa Ovary28 pag-aaral
- Kanser ng Endometrium25 pag-aaral
- Colorectal Cancer22 pag-aaral
- Kanser sa Prostate21 pag-aaral
- Kanser sa Suso17 pag-aaral
- Metastatic Cancer16 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg13 pag-aaral
- Kanser sa Pantog11 pag-aaral
- Kanser sa Pancreas11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.